 Erin Schenk
Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 27 | 2025 | 2329 | 3.740 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 19 | 2025 | 1046 | 3.310 |
Why?
| | Platinum | 1 | 2019 | 44 | 0.640 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1562 | 0.620 |
Why?
| | ErbB Receptors | 6 | 2024 | 603 | 0.600 |
Why?
| | Tumor Microenvironment | 6 | 2022 | 624 | 0.560 |
Why?
| | Mutation | 6 | 2024 | 3696 | 0.510 |
Why?
| | Sarcoma | 1 | 2017 | 177 | 0.480 |
Why?
| | Neoplasm Staging | 5 | 2025 | 1292 | 0.470 |
Why?
| | Biomarkers, Tumor | 8 | 2024 | 1179 | 0.460 |
Why?
| | Acrylamides | 2 | 2024 | 58 | 0.450 |
Why?
| | Aniline Compounds | 2 | 2024 | 96 | 0.440 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 259 | 0.410 |
Why?
| | Cytarabine | 1 | 2012 | 57 | 0.390 |
Why?
| | Protein Kinases | 1 | 2012 | 308 | 0.340 |
Why?
| | Receptor, ErbB-2 | 2 | 2024 | 326 | 0.330 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 382 | 0.320 |
Why?
| | Immunotherapy | 4 | 2020 | 589 | 0.310 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 880 | 0.310 |
Why?
| | Pyrimidines | 4 | 2024 | 449 | 0.300 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 581 | 0.300 |
Why?
| | Humans | 35 | 2025 | 128499 | 0.280 |
Why?
| | Neoplasms | 3 | 2021 | 2463 | 0.280 |
Why?
| | B7-H1 Antigen | 2 | 2020 | 190 | 0.270 |
Why?
| | Antineoplastic Agents | 4 | 2024 | 2042 | 0.250 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2012 | 592 | 0.250 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3178 | 0.240 |
Why?
| | Pemetrexed | 1 | 2024 | 32 | 0.230 |
Why?
| | Zinc Finger Protein Gli2 | 1 | 2024 | 4 | 0.230 |
Why?
| | Oncogenes | 1 | 2024 | 111 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2024 | 74 | 0.220 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.210 |
Why?
| | Survival Rate | 4 | 2024 | 1871 | 0.210 |
Why?
| | Bevacizumab | 1 | 2023 | 129 | 0.200 |
Why?
| | Receptors, Purinergic P1 | 1 | 2021 | 23 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2024 | 268 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2024 | 487 | 0.180 |
Why?
| | Carbon Monoxide | 1 | 2020 | 68 | 0.170 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7057 | 0.170 |
Why?
| | Benzimidazoles | 1 | 2021 | 160 | 0.170 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 229 | 0.170 |
Why?
| | Etoposide | 2 | 2019 | 148 | 0.170 |
Why?
| | Organophosphorus Compounds | 1 | 2020 | 79 | 0.170 |
Why?
| | Quinazolines | 1 | 2021 | 243 | 0.170 |
Why?
| | Picornaviridae | 1 | 2019 | 17 | 0.160 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 332 | 0.160 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 431 | 0.160 |
Why?
| | Adenosine | 1 | 2021 | 212 | 0.160 |
Why?
| | Carboplatin | 1 | 2019 | 140 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 633 | 0.160 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 360 | 0.150 |
Why?
| | Cisplatin | 2 | 2019 | 298 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1349 | 0.150 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 192 | 0.150 |
Why?
| | Aged | 8 | 2024 | 21976 | 0.150 |
Why?
| | Adaptive Immunity | 1 | 2019 | 157 | 0.150 |
Why?
| | Trans-Activators | 1 | 2020 | 384 | 0.140 |
Why?
| | Lymphocyte Count | 1 | 2017 | 150 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 177 | 0.140 |
Why?
| | Antigens, CD19 | 1 | 2017 | 115 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 878 | 0.130 |
Why?
| | Middle Aged | 9 | 2024 | 30923 | 0.130 |
Why?
| | Complement Activation | 1 | 2019 | 367 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2019 | 761 | 0.120 |
Why?
| | ROC Curve | 1 | 2017 | 502 | 0.120 |
Why?
| | Genomics | 1 | 2020 | 715 | 0.120 |
Why?
| | Male | 11 | 2024 | 63045 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2020 | 658 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 842 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2019 | 1856 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2020 | 532 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 749 | 0.120 |
Why?
| | Monocytes | 1 | 2017 | 546 | 0.110 |
Why?
| | Female | 10 | 2024 | 68268 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 1951 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2023 | 1172 | 0.110 |
Why?
| | Bortezomib | 1 | 2013 | 45 | 0.100 |
Why?
| | Mass Screening | 1 | 2020 | 1146 | 0.100 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.100 |
Why?
| | Lactams, Macrocyclic | 1 | 2013 | 49 | 0.100 |
Why?
| | Immunohistochemistry | 3 | 2022 | 1668 | 0.100 |
Why?
| | Benzoquinones | 1 | 2013 | 47 | 0.100 |
Why?
| | Checkpoint Kinase 1 | 1 | 2012 | 31 | 0.100 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 65 | 0.100 |
Why?
| | Pyrazines | 1 | 2013 | 86 | 0.100 |
Why?
| | Molecular Chaperones | 3 | 2002 | 182 | 0.100 |
Why?
| | Cell Cycle Checkpoints | 1 | 2012 | 95 | 0.100 |
Why?
| | Indoles | 2 | 2024 | 372 | 0.090 |
Why?
| | Medical Oncology | 2 | 2024 | 272 | 0.090 |
Why?
| | B7-1 Antigen | 2 | 2008 | 58 | 0.090 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 1490 | 0.090 |
Why?
| | Pyrazoles | 1 | 2012 | 404 | 0.080 |
Why?
| | Prospective Studies | 1 | 2020 | 7069 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1358 | 0.070 |
Why?
| | Interleukin-17 | 1 | 2008 | 107 | 0.070 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 181 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2020 | 227 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 168 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 170 | 0.070 |
Why?
| | Antibodies | 1 | 2008 | 394 | 0.070 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 385 | 0.060 |
Why?
| | Immunoglobulin M | 1 | 2007 | 272 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 366 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2022 | 1142 | 0.060 |
Why?
| | Antiporters | 2 | 2002 | 22 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2024 | 14472 | 0.060 |
Why?
| | T-Lymphocyte Subsets | 1 | 2007 | 409 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2345 | 0.060 |
Why?
| | Mice | 6 | 2024 | 16620 | 0.060 |
Why?
| | Immunoglobulins | 2 | 2002 | 158 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2023 | 10162 | 0.060 |
Why?
| | Prognosis | 2 | 2024 | 3780 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2002 | 196 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2024 | 169 | 0.050 |
Why?
| | Apoptosis | 1 | 2012 | 2437 | 0.050 |
Why?
| | Adult | 5 | 2024 | 35302 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1098 | 0.050 |
Why?
| | Autoimmunity | 1 | 2008 | 860 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2024 | 213 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 610 | 0.050 |
Why?
| | HLA-A Antigens | 1 | 2002 | 53 | 0.050 |
Why?
| | HLA-B Antigens | 1 | 2002 | 62 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2021 | 65 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 131 | 0.050 |
Why?
| | Cell Line | 3 | 2020 | 2741 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 254 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 479 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1199 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 11 | 0.040 |
Why?
| | Animals | 6 | 2024 | 34647 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3947 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 764 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 25 | 0.040 |
Why?
| | Gene Amplification | 1 | 2019 | 104 | 0.040 |
Why?
| | Complement C5a | 1 | 2019 | 67 | 0.040 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2024 | 2069 | 0.040 |
Why?
| | Histones | 1 | 2024 | 588 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2002 | 639 | 0.040 |
Why?
| | Complement Inactivating Agents | 1 | 2019 | 45 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 183 | 0.040 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 2 | 2008 | 13 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 428 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1404 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 276 | 0.040 |
Why?
| | Disease Progression | 1 | 2024 | 2604 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 1997 | 168 | 0.030 |
Why?
| | Interferon Type I | 1 | 1997 | 140 | 0.030 |
Why?
| | Ecosystem | 1 | 2020 | 566 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 758 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 622 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1464 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1923 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3387 | 0.020 |
Why?
| | Membrane Transport Proteins | 2 | 2002 | 149 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4874 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 5281 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2008 | 51 | 0.020 |
Why?
| | Perforin | 1 | 2007 | 19 | 0.020 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2007 | 16 | 0.020 |
Why?
| | Multiple Myeloma | 1 | 2008 | 125 | 0.020 |
Why?
| | Cell Communication | 1 | 2008 | 297 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2008 | 350 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2008 | 477 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2007 | 468 | 0.010 |
Why?
| | Vaccines | 1 | 2008 | 396 | 0.010 |
Why?
| | HLA-B15 Antigen | 1 | 2002 | 13 | 0.010 |
Why?
| | Histidine | 1 | 2002 | 58 | 0.010 |
Why?
| | Aspartic Acid | 1 | 2002 | 78 | 0.010 |
Why?
| | Glutamine | 1 | 2002 | 94 | 0.010 |
Why?
| | Substrate Specificity | 1 | 2002 | 366 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 1045 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 539 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2002 | 205 | 0.010 |
Why?
| | Cytokines | 1 | 2008 | 1994 | 0.010 |
Why?
| | Ligands | 1 | 2002 | 617 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2679 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 896 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 1170 | 0.010 |
Why?
| | Protein Conformation | 1 | 2002 | 854 | 0.010 |
Why?
| | Amino Acids | 1 | 2002 | 477 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1484 | 0.010 |
Why?
| | Peptides | 1 | 2002 | 915 | 0.010 |
Why?
| | Vincristine | 1 | 1997 | 109 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1997 | 228 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2002 | 814 | 0.010 |
Why?
| | Remission Induction | 1 | 1997 | 268 | 0.010 |
Why?
| | Protein Binding | 1 | 2002 | 2110 | 0.010 |
Why?
| | Doxorubicin | 1 | 1997 | 324 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1997 | 1291 | 0.010 |
Why?
|
|
Schenk's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|